Ambrx Biopharma Quarterly Cash Flow Statements Chart
Quarterly
|
Annual
Ambrx Biopharma Quarterly Cash Flow Statements Table
Quarterly
|
Annual
| Unit: USD | 2023-06-30 | 2023-03-31 |
|---|---|---|
| cash flows from operating activities: | ||
| net income | -17,826,000 | -15,302,000 |
| noncash adjustments reconciling net income to net cash from operating activities: | ||
| loss on impairment of intangible assets | ||
| share-based compensation expense | 2,886,000 | 1,938,000 |
| noncash lease expense | 654,000 | 712,000 |
| depreciation and amortization | 210,000 | 208,000 |
| amortization of intangible assets | 158,000 | 157,000 |
| accretion/amortization of investment securities | -27,000 | -299,000 |
| loss on disposal of property and equipment | 1,000 | |
| changes in operating assets and liabilities: | ||
| accounts receivable | -19,000 | 314,000 |
| prepaid and other current assets and other long-term assets | -864,000 | 159,000 |
| accounts payable | -732,000 | 3,886,000 |
| accrued liabilities | 3,084,000 | -4,010,000 |
| deferred revenue | ||
| operating lease liabilities | -673,000 | -731,000 |
| net cash from operating activities | -13,150,000 | -12,967,000 |
| capex | 0 | 0 |
| free cash flows | -13,150,000 | -12,967,000 |
| cash flows from investing activities: | ||
| purchases of marketable debt securities, available-for-sale | 0 | -40,645,000 |
| sales of marketable debt securities, available-for-sale | 3,464,000 | 50,799,000 |
| maturities of marketable debt securities, available-for-sale | 6,500,000 | 19,400,000 |
| purchases of property and equipment | ||
| net cash from investing activities | 9,181,000 | 29,554,000 |
| cash flows from financing activities: | ||
| proceeds from short-term bridge loan | ||
| repayment of short-term bridge loan | ||
| payments of directors and officers insurance premium financing agreement | -373,000 | -559,000 |
| proceeds from issuance of common stock for cash, net of issuance costs | ||
| issuance of ordinary shares for cash through registered direct offering with a related party, net of issuance costs | ||
| issuance of ordinary shares for cash pursuant to employee stock purchase programs | ||
| payments of costs for the issuance of ordinary shares | ||
| net cash from financing activities | 82,650,000 | 77,221,000 |
| net increase in cash, cash equivalents and restricted cash | 78,681,000 | 93,808,000 |
| cash, cash equivalents and restricted cash, beginning of period | 0 | 56,441,000 |
| cash, cash equivalents and restricted cash, end of period | 78,681,000 | 150,249,000 |
| supplemental information: | ||
| cash paid for interest | ||
| cash paid for income taxes | ||
| noncash investment and financing activities: | ||
| property and equipment costs in accounts payable and accrued liabilities | -268,000 | 545,000 |
| direct offering costs in accounts payable and accrued liabilities | ||
| unsettled trade of marketable debt securities, available-for-sale | ||
| proceeds from issuance of ordinary shares, net of issuance costs | 77,780,000 | |
| noncash adjustments reconciling net income to cash flows from operating activities: | ||
| change in fair value of redeemable noncontrolling interests | ||
| acquisition of intangible assets | ||
| proceeds from directors and officers insurance premium financing agreement | ||
| payments to acquire the ambrx shanghai noncontrolling interests | ||
| payments of costs for the issuance of series b preferred shares | ||
| effect of exchange rate changes on cash, cash equivalents and restricted cash | ||
| rou assets and lease liabilities obtain through reassessment of an existing lease | ||
| conversion of convertible preferred shares into ordinary shares | ||
| reclassification of redeemable noncontrolling interests from temporary equity to current liabilities | ||
| accretion of redeemable noncontrolling interests to fair value | ||
| deferred initial public offering costs in accounts payable and accrued liabilities | ||
| reclassification of accumulated other comprehensive loss upon settlement of redeemable noncontrolling interests |
We provide you with 20 years of cash flow statements for Ambrx Biopharma stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Ambrx Biopharma stock. Explore the full financial landscape of Ambrx Biopharma stock with our expertly curated income statements.
The information provided in this report about Ambrx Biopharma stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.